Related Experiment Video

Updated: Mar 25, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.7K

Clinical trials of antiangiogenic therapy for hepatocellular carcinoma

Akinobu Taketomi1

  • 1Department of Gastroenterological Surgery I, Graduate School of Medicine, Hokkaido University, North 15 West 7, Kita-ku, Sapporo, 060-8638, Japan. taketomi@med.hokudai.ac.jp.

International Journal of Clinical Oncology
|February 23, 2016
PubMed

Insights

Antiangiogenic agents show promise for liver cancer, but only sorafenib is approved. Further research is needed to combine these therapies with sorafenib for better outcomes in advanced hepatocellular carcinoma.

Area of Science:

  • Oncology
  • Hepatology
  • Medical Pharmacology

Background:

  • Angiogenesis, the formation of new blood vessels, is a critical process in tumor growth and a key therapeutic target.
  • Hepatocellular carcinoma (HCC) treatment has been advanced by targeting angiogenesis, yet challenges remain in optimizing therapeutic strategies.

Purpose of the Study:

  • To review clinical trial data on antiangiogenic agents for hepatocellular carcinoma (HCC).
  • To evaluate the efficacy of antiangiogenic therapies in advanced HCC and identify future research directions.

Main Methods:

  • Systematic literature search of PubMed for clinical trials, focusing on phase III trials in advanced HCC.
  • Analysis of data from randomized controlled trials investigating antiangiogenic agents, including sorafenib.

Main Results:

  • Sorafenib is the only approved systemic drug for advanced HCC, demonstrating survival benefits in two large phase III trials.
  • Subsequent phase III trials of other antiangiogenic agents have not shown improved survival compared to sorafenib-based protocols.
  • Ongoing trials explore combinations of antiangiogenic agents with chemotherapy, transarterial chemoembolization, and surgical resection.

Conclusions:

  • While sorafenib offers a survival advantage in advanced HCC, further research is crucial.
  • Optimizing combination therapies involving antiangiogenic agents and sorafenib is a key area for future investigation to improve patient outcomes.
Keywords:
AngiogenesisAntiangiogenic therapyHepatocellular carcinomaSorafenib

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

10.0K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
11.1K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K